234 related articles for article (PubMed ID: 31942031)
1. MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.
Casciano JC; Perry C; Cohen-Nowak AJ; Miller KD; Vande Voorde J; Zhang Q; Chalmers S; Sandison ME; Liu Q; Hedley A; McBryan T; Tang HY; Gorman N; Beer T; Speicher DW; Adams PD; Liu X; Schlegel R; McCarron JG; Wakelam MJO; Gottlieb E; Kossenkov AV; Schug ZT
Br J Cancer; 2020 Mar; 122(6):868-884. PubMed ID: 31942031
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
3. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
4. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer.
Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H
J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
[TBL] [Abstract][Full Text] [Related]
6. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
7. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
8. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract][Full Text] [Related]
10. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
11. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
12. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer.
Luo L; Tang H; Ling L; Li N; Jia X; Zhang Z; Wang X; Shi L; Yin J; Qiu N; Liu H; Song Y; Luo K; Li H; He Z; Zheng G; Xie X
Oncogene; 2018 Nov; 37(47):6166-6179. PubMed ID: 30002443
[TBL] [Abstract][Full Text] [Related]
13. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
[TBL] [Abstract][Full Text] [Related]
15. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.
Rädler PD; Wehde BL; Triplett AA; Shrestha H; Shepherd JH; Pfefferle AD; Rui H; Cardiff RD; Perou CM; Wagner KU
Nat Commun; 2021 Jun; 12(1):3742. PubMed ID: 34145248
[TBL] [Abstract][Full Text] [Related]
16. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
[TBL] [Abstract][Full Text] [Related]
17. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
18. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
19. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
20. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P
BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]